Trials / Terminated
TerminatedNCT05103826
A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer
A Phase I Study to Evaluate Safety 、Tolerability 、 Pharmacokinetics and Efficacy of SHR6390 in Combination With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to assess the safety 、tolerability 、 pharmacokinetics and efficacy of SHR6390 combined with famitinib in the treatment of ER + / HER2- advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR6390、Famitinib | SHR6390, oral;Famitinib, oral. |
Timeline
- Start date
- 2021-10-25
- Primary completion
- 2023-06-15
- Completion
- 2023-06-15
- First posted
- 2021-11-02
- Last updated
- 2023-08-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05103826. Inclusion in this directory is not an endorsement.